PT  - JOURNAL ARTICLE
AU  - Kurahashi, Yukiya
AU  - Furukawa, Koichi
AU  - Sutandhio, Silvia
AU  - Tjan, Lidya Handayani
AU  - Iwata, Sachiyo
AU  - Sano, Shigeru
AU  - Tohma, Yoshiki
AU  - Ohkita, Hiroyuki
AU  - Nakamura, Sachiko
AU  - Nishimura, Mitsuhiro
AU  - Arii, Jun
AU  - Kiriu, Tatsunori
AU  - Yamamoto, Masatsugu
AU  - Nagano, Tatsuya
AU  - Nishimura, Yoshihiro
AU  - Mori, Yasuko
TI  - Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination
AID  - 10.1101/2022.02.24.22271262
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.24.22271262
4099  - http://medrxiv.org/content/early/2022/02/26/2022.02.24.22271262.short
4100  - http://medrxiv.org/content/early/2022/02/26/2022.02.24.22271262.full
AB  - The SARS-CoV-2 variant Omicron is now under investigation. We evaluated cross-neutralizing activity against Omicron in COVID-19 convalescent patients (n=23) who had received two doses of an mRNA vaccination (BNT162b2 or mRNA-1273). Surprisingly and interestingly, after the second vaccination, the subjects’ neutralizing antibody titers including that against Omicron all became seropositive, and significant fold-increases (21.1–52.0) were seen regardless of the subjects’ disease severity. Our findings thus demonstrate that at least two doses of mRNA vaccination to SARS-CoV-2 convalescent patients can induce cross-neutralizing activity against Omicron.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Hyogo prefectural government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Kobe University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.